|
1
|
Pectasides D, Pectasides E and
Economopoulos T: Fallopian tube carcinoma: a review. Oncologist.
11:902–912. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rosenblatt KA, Weiss NS and Schwartz SM:
Incidence of malignant fallopian tube tumors. Gynecol Oncol.
35:236–239. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Riska A, Leminen A and Pukkala E:
Sociodemographic determinations of incidence of primary fallopian
tube carcinoma, Finland 1953–97. Int J Cancer. 104:643–645.
2003.PubMed/NCBI
|
|
4
|
Wethington SL, Herzog TJ, Seshan VE, et
al: Improved survival for fallopian tube cancer: a comparison of
clinical characteristics and outcome for primary fallopian tube and
ovarian cancer. Cancer. 113:3298–3306. 2008. View Article : Google Scholar
|
|
5
|
Sedlis A: Primary carcinoma of the
fallopian tube. Obstet Gynecol Surv. 16:209–226. 1961. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
World Health Organization Classification
of Tumours. Pathology & Genetics. Tumours of the Breast and
Female Genital Organs. IARC Press; Lyon: 2003
|
|
7
|
Hoskins WJ, McGuire WP, Brady MF, et al:
The effect of diameter of largest residual disease on survival
after primary cytoreductive surgery in patients with suboptimal
residual epithelial ovarian carcinoma. Am J Obstet Gynecol.
170:974–979. 1994. View Article : Google Scholar
|
|
8
|
Eisenhauer EA, Therasse P, Bogaerts J, et
al: New response evaluation criteria in solid tumours: revised
RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009.
View Article : Google Scholar
|
|
9
|
Gadducci A, Landoni F, Sartori E, et al:
Analysis of treatment failures and survival of patients with
fallopian tube carcinoma: a Cooperation Task Force (CTF) study.
Gynecol Oncol. 81:150–159. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Roh HJ, Kim DY, Joo WD, et al: Hepatic
resection as part of secondary cytoreductive surgery for recurrent
ovarian cancer involving the liver. Arch Gynecol Obstet.
284:1223–1229. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ushijima K: Treatment of recurrent ovarian
cancer - at first relapse. J Oncol. 2010:4974292010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Klein M, Rosen AC, Lahousen M, et al:
Lymphadenectomy in primary carcinoma of the fallopian tube. Cancer
Lett. 147:63–66. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ajithkumar TV, Minimole AL, John MM and
Ashokkumar OS: Primary fallopian tube carcinoma. Obstet Gynecol
Surv. 60:247–252. 2005. View Article : Google Scholar
|
|
14
|
Peter WA III, Andersen WA, Hopkins MP, et
al: Prognostic features of carcinoma of the fallopian tube. Obstet
Gynecol. 71:757–762. 1988.PubMed/NCBI
|
|
15
|
Baekelandt M, Joruun Nesbakken A,
Kristensen GB, et al: Carcinoma of the fallopian tube. Cancer.
89:2076–2084. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Gemignani ML, Hensley ML, Cohen R, et al:
Paclitaxel-based chemotherapy in carcinoma of the fallopian tube.
Gynecol Oncol. 80:16–20. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Katsumata N, Yasuda M, Takahashi F, et al:
Dose-dense paclitaxel once a week in combination with carboplatin
every 3 weeks for advanced ovarian cancer: a phase 3, open-label,
randomised controlled trial. Lancet. 374:1331–1338. 2009.
View Article : Google Scholar
|
|
18
|
Anderson B, Turner DA and Benda J: Ovarian
sarcoma. Gynecol Oncol. 26:183–192. 1987. View Article : Google Scholar
|
|
19
|
Tate Thigpen J, Blessing JA, DeGeest K, et
al: Cisplatin as initial chemotherapy in ovarian carcinosarcima: a
Gynecologic Oncology Group study. Gynecol Oncol. 93:336–339.
2004.
|
|
20
|
Eddy GL, Copeland LJ and Gershenson DM:
Second-look laparotomy in fallopian tube carcinoma. Gynecol Oncol.
19:182–186. 1984. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Podratz KC, Podczaski ES, Gaffey TA, et
al: Primary carcinoma of the fallopian tube. Am J Obstet Gynecol.
154:1319–1326. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huber-Buchholz MM, Buchholz NP and
Staehelin J: Analysis of 23 cases of primary carcinoma of the
fallopian tube over 50 years. J Obstet Gynaecol Res. 22:193–199.
1996.PubMed/NCBI
|
|
23
|
Meng ML, Gan-Gao, Scheng-Sun, et al:
Diagnosis of primary adenocarcinoma of the fallopian tube. J Cancer
Res Clin Oncol. 110:136–140. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Timor-Tritsch IE and Rottem S:
Transvaginal ultrasonographic study of the fallopian tube. Obstet
Gynecol. 70:424–428. 1987.PubMed/NCBI
|
|
25
|
Subramanyam BR, Raghavendra BN, Whalen CA,
et al: Ultrasonic features of fallopian tube carcinoma. J
Ultrasound Med. 3:391–393. 1984.PubMed/NCBI
|
|
26
|
Kol S, Gal D, Friedman M and Paldi E:
Preoperative diagnosis of fallopian tube carcinoma by transvaginal
sonography and CA-125. Gynecol Oncol. 37:129–131. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ajjimakorn S, Bhamarapravati Y and
Israngura N: Ultrasound appearance of fallopian tube carcinoma. J
Clin Ultrasound. 16:516–518. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kurjak A, Kupesic S, Sparac V and Kosuta
D: Three-dimensional ultrasonographic and power Doppler
characterization of ovarian lesions. Ultrasound Obstet Gynecol.
16:365–371. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
McMurray EH, Jacobs AJ, Perez CA, et al:
Carcinoma of the fallopian tube. Management and sites of failure.
Cancer. 58:2070–2075. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rosen AC, Klein M, Hafner E, et al:
Management and prognosis of primary fallopian tube carcinoma.
Austrian Cooperative Study Group for Fallopian Tube Carcinoma.
Gynecol Obstet Invest. 47:45–51. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Tokunaga T, Miyazaki K, Matsuyama S, et
al: Serial measurement of CA 125 in patients with primary carcinoma
of the fallopian tube. Gynecol Oncol. 36:335–337. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Hefler LA, Rosen AC, Graf AH, et al: The
clinical value of serum concentrations of cancer antigen 125 in
patients with primary fallopian tube carcinoma: a multicenter
study. Cancer. 89:1555–1560. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Moore KN, Moxley KM, Fader AN, et al:
Serous fallopian tube carcinoma: a retrospective,
multi-institutional case-control comparison to serous
adenocarcinoma of the ovary. Gynecol Oncol. 107:398–403. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pectasides D, Pectasides E, Papaxoinis G,
et al: Primary fallopian tube carcinoma: results of a retrospective
analysis of 64 patients. Gynecol Oncol. 115:97–101. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kosary C and Trimble EL: Treatment and
survival for women with fallopian tube carcinoma: a
population-based study. Gynecol Oncol. 86:190–191. 2002. View Article : Google Scholar
|
|
36
|
Kurman RJ and Shih IeM: Molecular
pathogenesis and extraovarian origin of epithelial ovarian cancer -
shifting the paradigm. Hum Pathol. 42:918–931. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Berek JS, Crum C and Friedlander M: Cancer
of the ovary, fallopian tube, and peritoneum. Int J Gynaecol
Obstet. 119:S118–S129. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Dunn MS, Manahan KJ and Geisler JP:
Primary carcinoma of the fallopian tube and epithelial ovarian
carcinoma: a case-control analysis. J Reprod Med. 53:691–694.
2008.PubMed/NCBI
|
